|1.||Tao, Yuan-Xiang: 1 article (01/2008)|
|2.||Guan, Yun: 1 article (01/2008)|
|3.||Yaster, Myron: 1 article (01/2008)|
|4.||Park, Jang-Su: 1 article (01/2008)|
|5.||Guan, Xiaowei: 1 article (01/2008)|
|6.||Shih, Ming-Hung: 1 article (01/2008)|
|7.||Raja, Srinivasa N: 1 article (01/2008)|
|8.||Xu, Ji-Tian: 1 article (01/2008)|
|9.||Donato, Giuseppe: 1 article (11/2006)|
|10.||Gratteri, Santo: 1 article (11/2006)|
03/05/1999 - "Pretreatment with CFM-2 delayed the progression of seizure rank during repeated administration of pentylentetrazole. "
08/20/1999 - "In particular, CFM-2 has been proven to possess anticonvulsant activity in various models of seizures, acting as alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate (AMPA) receptor antagonist."
03/05/1999 - "Thus, the administration of a challenge dose of pentylentetrazole (15 mg kg(-1) i.p.) or picrotoxin (1.5 mg kg(-1) i.p.) 15 or 30 days after the end of the repeated treatment showed that animals treated with CFM-2 were significantly protected against seizures induced by pentylentetrazole or picrotoxin. "
03/05/1999 - "At the end of the period of repeated pentylentetrazole treatment (6 weeks) the mean seizure score was 0 in vehicle treated controls, 4.3 in animals treated with vehicle + pentylentetrazole, 2.2 in rats treated chronically with CFM-2 (20 micromol kg(-1) i.p.) + pentylentetrazole and 1.0 in rats treated repeatedly with CFM-2 (50 micromol kg(-1) i.p.) + pentylenetetrazole. "
11/01/2006 - "CFM-2 [1-(4-aminophenyl)-3,5-dihydro-7,8-dimethoxy-4H-2,3-benzodiazepin-4-one] and THIQ-10c [N-acetyl-1-(4-chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline], are two non-competitive 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propionic acid (AMPA) receptor antagonists, which demonstrated to antagonize generalized tonic-clonic seizures in different animal models. "
03/05/1999 - "The data suggest that, following repeated treatment, tolerance to the novel AMPA receptor antagonists does not develop (CFM-1 in genetically epilepsy-prone rats and CFM-2 in the pentylentetrazole kindling model of epilepsy). "
03/05/1999 - "The non-selective alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) receptor antagonists, 2,3-benzodiazepine derivatives CFM-1 (3,5-dihydro-7,8-dimethoxy-1-phenyl-4H-2,3-benzodiazepin-4-one) and CFM-2 (1-(4'-aminophenyl)-3,5-dihydro-7,8-dimethoxy-4H-2,3-benzodiazepin -4-one), following intraperitoneal (i.p.) administration, were studied against audiogenic seizures in genetically epilepsy-prone rats (GEPRs) or pentylenetetrazole induced kindling in rats. "
|1.||AMPA Receptors (AMPA Receptor)
|4.||2- acetyl- 1- (4'- chlorophenyl)- 6,7- dimethoxy- 1,2,3,4- tetrahydroisoquinoline
|7.||propionic acid (potassium propionate)